Mineralys’ 200% Surge and the Fund’s Bold Move

Suvretta Capital Management, a U.S.-based investment adviser, reported in a November 14 SEC filing that it increased its stake in Mineralys Therapeutics during the third quarter. The fund acquired 387,641 additional shares, bringing total holdings to 2.13 million shares worth $80.85 million as of September 30. The fund reported 93 total positions for the quarter. (A footnote: 93 positions is roughly the number of things a person might worry about if they were a fund manager and also a neurotic parrot.)


